Sarcoma  >>  adavosertib (AZD1775)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
adavosertib (AZD1775) / AstraZeneca
NCT03668340: AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Active, not recruiting
2
49
US
AZD1775
Dana-Farber Cancer Institute, AstraZeneca
Uterine Cancer
12/24
12/25

Download Options